{"nctId":"NCT01106677","briefTitle":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","startDateStruct":{"date":"2010-05"},"conditions":["Diabetes Mellitus, Type 2"],"count":1284,"armGroups":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin","Drug: Metformin immediate release"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin","Drug: Metformin immediate release"]},{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sitagliptin","Drug: Metformin immediate release"]},{"label":"Placebo/Sitagliptin","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Sitagliptin","Drug: Metformin immediate release"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Canagliflozin","otherNames":[]},{"name":"Sitagliptin","otherNames":[]},{"name":"Metformin immediate release","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM and be currently treated with metformin IR\n* Patients in the study must have a HbA1c between \\>=7 and \\<=10.5%\n* Patients must have a fasting plasma glucose (FPG) \\<270 mg/dL (15 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.060"},{"groupId":"OG001","value":"-0.79","spread":"0.044"},{"groupId":"OG002","value":"-0.94","spread":"0.044"},{"groupId":"OG003","value":"-0.82","spread":"0.044"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences between each canagliflozin or sitagliptin group and placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"57.8","spread":null},{"groupId":"OG003","value":"54.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"2.576"},{"groupId":"OG001","value":"-27.3","spread":"1.873"},{"groupId":"OG002","value":"-37.8","spread":"1.893"},{"groupId":"OG003","value":"-20.2","spread":"1.908"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Post-prandial Glucose From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.79","spread":"4.860"},{"groupId":"OG001","value":"-47.9","spread":"3.305"},{"groupId":"OG002","value":"-57.1","spread":"3.356"},{"groupId":"OG003","value":"-49.3","spread":"3.340"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.3"},{"groupId":"OG001","value":"-3.7","spread":"0.2"},{"groupId":"OG002","value":"-4.2","spread":"0.2"},{"groupId":"OG003","value":"-1.2","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.829"},{"groupId":"OG001","value":"-3.84","spread":"0.602"},{"groupId":"OG002","value":"-5.06","spread":"0.605"},{"groupId":"OG003","value":"-1.83","spread":"0.611"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"3.6"},{"groupId":"OG001","value":"1.6","spread":"2.6"},{"groupId":"OG002","value":"-1.4","spread":"2.6"},{"groupId":"OG003","value":"1.0","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.3"},{"groupId":"OG001","value":"10.4","spread":"0.9"},{"groupId":"OG002","value":"12.1","spread":"1.0"},{"groupId":"OG003","value":"5.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"0.047"},{"groupId":"OG001","value":"-0.88","spread":"0.047"},{"groupId":"OG002","value":"-0.73","spread":"0.047"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.2","spread":"1.814"},{"groupId":"OG001","value":"-35.2","spread":"1.833"},{"groupId":"OG002","value":"-17.7","spread":"1.848"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"0.2"},{"groupId":"OG001","value":"-4.2","spread":"0.2"},{"groupId":"OG002","value":"-1.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.53","spread":"0.615"},{"groupId":"OG001","value":"-4.65","spread":"0.618"},{"groupId":"OG002","value":"-0.66","spread":"0.625"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"2.4"},{"groupId":"OG001","value":"2.7","spread":"2.4"},{"groupId":"OG002","value":"-0.4","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52","description":"The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"1.0"},{"groupId":"OG001","value":"13.3","spread":"1.1"},{"groupId":"OG002","value":"6.0","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":183},"commonTop":["Diarrhoea","Urinary tract infection","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}}